FY2025 EPS Estimates for Biogen Reduced by Cantor Fitzgerald

Biogen Inc. (NASDAQ:BIIB - Free Report) - Equities research analysts at Cantor Fitzgerald cut their FY2025 earnings per share (EPS) estimates for shares of Biogen in a report released on Wednesday, April 9th. Cantor Fitzgerald analyst E. Schmidt now expects that the biotechnology company will post earnings of $14.74 per share for the year, down from their previous forecast of $16.13. The consensus estimate for Biogen's current full-year earnings is $15.83 per share.

Several other brokerages also recently weighed in on BIIB. Bank Of America (Bofa) cut their target price on shares of Biogen from $178.00 to $163.00 and set a "neutral" rating for the company in a research note on Tuesday, February 11th. Royal Bank of Canada lowered their price objective on Biogen from $231.00 to $225.00 and set an "outperform" rating for the company in a research report on Thursday, February 13th. Scotiabank decreased their price target on Biogen from $244.00 to $224.00 and set a "sector outperform" rating on the stock in a research note on Thursday, February 13th. StockNews.com cut shares of Biogen from a "strong-buy" rating to a "buy" rating in a research report on Saturday, December 28th. Finally, BMO Capital Markets dropped their price target on shares of Biogen from $156.00 to $139.00 and set a "market perform" rating for the company in a research report on Thursday, February 13th. Eighteen equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $213.15.

Biogen Price Performance

Shares of NASDAQ BIIB traded down $0.56 during trading on Friday, reaching $116.42. The company had a trading volume of 519,415 shares, compared to its average volume of 1,351,037. The company has a current ratio of 1.35, a quick ratio of 0.90 and a debt-to-equity ratio of 0.27. Biogen has a twelve month low of $110.04 and a twelve month high of $238.00. The stock has a 50-day moving average price of $135.71 and a two-hundred day moving average price of $152.96. The stock has a market capitalization of $17.04 billion, a PE ratio of 10.40, a price-to-earnings-growth ratio of 1.51 and a beta of 0.06.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share for the quarter, topping analysts' consensus estimates of $3.43 by $0.01. Biogen had a net margin of 16.87% and a return on equity of 14.98%.

Hedge Funds Weigh In On Biogen

Large investors have recently bought and sold shares of the stock. Larson Financial Group LLC raised its position in shares of Biogen by 640.9% during the fourth quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company's stock valued at $25,000 after buying an additional 141 shares during the last quarter. Lee Danner & Bass Inc. acquired a new position in Biogen in the 4th quarter valued at approximately $25,000. Colonial Trust Co SC lifted its position in shares of Biogen by 9,300.0% in the 4th quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 186 shares during the period. OFI Invest Asset Management acquired a new stake in shares of Biogen during the 4th quarter worth approximately $32,000. Finally, SRS Capital Advisors Inc. bought a new stake in shares of Biogen during the fourth quarter valued at approximately $33,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Stephen A. Sherwin sold 8,760 shares of the company's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $150.02, for a total transaction of $1,314,175.20. Following the completion of the transaction, the director now directly owns 11,318 shares in the company, valued at $1,697,926.36. The trade was a 43.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.16% of the company's stock.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.